Fatty acid synthase (FASN), an enzyme that drives de novo lipogenesis, plays a relevant role in metabolic disorders such as obesity, non-alcoholic fatty liver disease (NAFLD) or type 2 diabetes.

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases ...

Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.

Sagimet Biosciences has announced the progression of its lead candidate, denifanstat, an oral, selective fatty acid synthase ...

Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

9 to 11. The presentation will spotlight the company’s lead drug candidate, denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor, which has shown promising results in the Phase ...